Halozyme Therapeutics, Inc.

Submit Your Information

Company Name	Halozyme Therapeutics, Inc.
Stock Symbol	HALO
Status	1

On January 16, 2018, an abstract was published detailing a study of Halozyme’s drug PEGPH20 as a treatment for pancreatic cancer in combination with the cancer drug mFFOX. The abstract’s authors concluded that the addition of PEGPH20 to mFFOX appears to be detrimental, noting that patients who used the combination experienced higher levels of diarrhea, fatigue, nausea, and vomiting. On this news, Halozyme’s share price fell $1.76, or nearly 9%, to close at $17.98 on January 17, 2018, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Halozyme Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before November 30, -0001?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments